Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 16/20 | 0.41 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26015660 | 0.91 | FOLH1 (0.41) | ITGB1ITGA5FOLH1CALCRL | |
| SCHEMBL26024621 | 0.91 | FOLH1 (0.41) | FOLH1CALCRL | |
| SCHEMBL26027291 | 0.90 | FOLH1 (0.40) | FOLH1 | |
| SCHEMBL26028187 | 0.89 | ITGB1 (0.49) | ITGB1ITGA5FOLH1CALCRL | |
| SCHEMBL26015665 | 0.89 | SSTR3 (0.41) | ITGB1ITGA5FOLH1CALCRLHDAC3 | |
| SCHEMBL26027705 | 0.89 | FOLH1 (0.45) | ITGB1ITGA5FOLH1 | |
| SCHEMBL25362754 | 0.88 | FOLH1 (0.38) | FOLH1CALCRLHDAC3HDAC4HDAC1 | |
| SCHEMBL25362741 | 0.88 | FOLH1 (0.38) | FOLH1CALCRLHDAC3HDAC4HDAC1 | |
| SCHEMBL26015711 | 0.88 | HDAC8 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL26015581 | 0.87 | FOLH1 (0.38) | ITGB1ITGA5FOLH1CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | ITGB1 2939/4885ITGA5 3119/4885FOLH1 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.